There is an urgent need in oncology to link molecular aberrations in tumors with therapeutics that can be administered in a personalized fashion. One approach identifies synthetic-lethal genetic interactions or emergent dependencies that cancer cells acquire in the presence of specific mutations. Using breast epithelial cells as a base we have developed methodologies to connect tumor mutations with drug sensitivity using quantitative functional genomic screens to create chemical-genetic interaction maps. The focus of the lab is to use these maps to uncover new synthetic-lethal relationships and identify new biomarkers for targeted as well as chemotherapy. I will describe new approaches to use these quantitative maps to uncover drug mechanism of action as well as integrate with cancer cell line collections to predict drug responses in cancer.

Citation Format: Sourav Bandyopadhyay. Chemical-genetic interaction maps for precision therapies in breast and ovarian cancers [abstract]. In: Proceedings of the AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; Jan 4-7, 2017; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2017;16(10 Suppl):Abstract nr IA20.